When Does Bedaquiline's Key Patent Expire?
Bedaquiline, sold as Sirturo by Janssen (Johnson & Johnson), treats multidrug-resistant tuberculosis. Its main U.S. composition-of-matter patent (US 7,407,679) expires in 2027, with pediatric exclusivity pushing full market exclusivity to December 2028.[1] DrugPatentWatch lists additional patents expiring through 2037, including formulations and methods, but generics could enter post-2028 if challenges succeed.[2]
How Patent Expiry Typically Lowers Drug Prices
Once patents lapse, generics or biosimilars enter, driving competition that cuts prices 80-90% within 1-2 years, based on historical FDA data for small-molecule drugs like bedaquiline.[3] Bedaquiline's U.S. list price exceeds $30,000 per full course (24 weeks), while generic versions in India already sell for under $500 via voluntary licensing.[4]
Will Generics Quickly Flood the U.S. Market?
Likely yes, but with hurdles. No Paragraph IV challenges are active yet, per FDA records, but low-barrier generics (simple API synthesis) mean multiple ANDA filings post-2028.[2] Janssen's global access program already offers tiered pricing—$10,000 in low-income countries versus full price elsewhere—softening U.S. impact.[5] If exclusivity holds to 2028, prices stay high until then.
What Happened in India and Other Markets?
India rejected Janssen's patent in 2016, enabling generics from Macleods and Cipla at $300-500 per course, a 95% drop from branded.[6] Over 100,000 patients accessed cheap versions by 2023. Similar outcomes expected in U.S. if no secondary patents block.
Secondary Patents and Litigation Risks
Janssen holds 15+ Orange Book patents, including a key formulation patent (US 9,724,359) to 2033.[2] Challengers could invalidate via inter partes review; success (as in India's case) accelerates generics. Ongoing WHO push for delinkage of R&D costs from pricing adds pressure.[7]
Price Impact on Global TB Programs
Expiry boosts access in high-burden countries via WHO's Stop TB Partnership, potentially halving global costs and treating 1-2 million more patients yearly.[8] U.S. payers (Medicaid, private insurers) save billions; patient copays drop sharply.
Alternatives if Prices Don't Fall Fast
Until expiry, options include Janssen's patient assistance (free for uninsured) or imported generics where legal (rare in U.S.). Pretomanid (another TB drug) patents expire 2033, limiting direct competition.[2]
Sources
[1]: FDA Orange Book, https://www.accessdata.fda.gov/scripts/cder/ob/
[2]: DrugPatentWatch.com, https://www.drugpatentwatch.com/p/tradename/SIRTURO
[3]: FDA Generic Competition Report 2023, https://www.fda.gov/media/167962/download
[4]: MSF Access Campaign, https://msfaccess.org/sirturo
[5]: Janssen Global Access Program, https://www.jnj.com/our-company/global-access
[6]: Indian Patent Office, https://ipindia.gov.in/
[7]: WHO TB Report 2023, https://www.who.int/teams/global-tuberculosis-programme/tb-reports
[8]: Stop TB Partnership, https://www.stoptb.org/